Liminatus Pharma taps Synex as CRO for IBC101 Phase 1/2a study in South Korea
LIMN•South Korea trial execution
Work targets clinical execution in South Korea following MFDS authorization for a relapsed or refractory DLBCL study. Seoul St. Mary’s Hospital was named lead site for the Phase 1/2a trial.
Milestone-based contract terms
The contract uses milestone-based payments tied to patient enrollment, database lock, and completion of the clinical study report.
Synex named CRO for Phase 1/2a study
Liminatus Pharma engaged Korea-based Synex Consulting as CRO to support Phase 1/2a development of IBC101 CD19xCD22 bivalent CAR-T.
